Advertisement Bausch & Lomb to acquire Eyeonics - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Bausch & Lomb to acquire Eyeonics

Bausch & Lomb, the global eye health company, has entered into a definitive agreement to acquire Eyeonics, an ophthalmic medical device company headquartered in Aliso Viejo, California.

Upon completion of the acquisition, Eyeonics’s operations will become part of Bausch & Lomb’s surgical business, which offers a complete line of standard intraocular lenses, phacoemulsification equipment, vitreoretinal and refractive products to ophthalmologists worldwide. The US surgical business will be led by Andy Corley, Eyeonics’s co-founder, chairman, and CEO.

Ronald Zarrella, chairman and CEO, Bausch & Lomb, said: “This acquisition immediately places Bausch & Lomb into the rapidly expanding premium intraocular lens (IOL) market. The crystalens technology complements our existing cataract surgical business, including our Stellaris Vision Enhancement System and our portfolio of monofocal IOLs.”